Sensor-Augmented Insulin-Pump Therapy in New-onset Diabetes After Transplantation
Status:
Completed
Trial end date:
2018-05-01
Target enrollment:
Participant gender:
Summary
The SAPT-NODAT study will test the hypotheses that intensive subcutaneous insulin treatment
with short acting insulin, applied continuously through an insulin pump, (i) improves
glycemic control, (ii) reduces the prevalence of NODAT and prediabetes, and (iii) offers
further β-cell protection, in comparison to the standard of care control group, and the basal
insulin treatment group. In the SAPT-NODAT study, we will employ sensor-augmented
insulin-pump technology, which performs like a semi-closed loop to prevent hypoglycemic
events. Patients in the SAPT-NODAT study will be followed through 24 months
post-transplantation.